Jaguar Health, Inc. (NASDAQ:JAGX)

COMMUNIQUÉ DE PRESSE

publié le 21/08/2025 à 15:00, il y a 8 mois 30 jours

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs
Jaguar Health announces conditional FDA approval of Canalevia-CA1 for CID in dogs and strategic plans to expand indication for general diarrhea treatment globally. Participation in 2025 Animal Health Summit

FDA Approval Canalevia-CA1 Partnerships Animal Health Diarrhea Treatment
BRÈVE

publiée le 19/08/2025 à 22:20, il y a 9 mois 1 jour

Jaguar Health annonce l'approbation de toutes les propositions lors de son assemblée annuelle

Crofelemer Jaguar Health Approbation De La FDA Assemblée Annuelle Stratégie De Partenariat
BRÈVE

publiée le 19/08/2025 à 22:20, il y a 9 mois 1 jour

Jaguar Health Announces Approval of All Proposals at Annual Meeting

Crofelemer FDA Approval Jaguar Health Annual Meeting Partnership Strategy
COMMUNIQUÉ DE PRESSE

publié le 19/08/2025 à 22:15, il y a 9 mois 1 jour

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders
Jaguar CEO Lisa Conte to provide updates on crofelemer trial results and regulatory pathway at Emerging Growth Conference. Annual meeting results and company strategy also discussed

Crofelemer Jaguar Health Lisa Conte Emerging Growth Conference Regulatory Pathway
BRÈVE

publiée le 19/08/2025 à 15:05, il y a 9 mois 1 jour

Napo Pharmaceuticals, filiale de Jaguar Health, sollicite l'avis de la FDA sur le crofelemer pour le traitement d'une maladie pédiatrique rare.

Napo Pharmaceuticals Jaguar Health Réunion De La FDA Traitement MVID Essais Crofelemer
BRÈVE

publiée le 19/08/2025 à 15:05, il y a 9 mois 1 jour

Jaguar Health's Napo Pharmaceuticals Seeks FDA Guidance on Crofelemer for Rare Pediatric Disease

Napo Pharmaceuticals Jaguar Health Crofelemer Trials FDA Meeting MVID Treatment
COMMUNIQUÉ DE PRESSE

publié le 19/08/2025 à 15:00, il y a 9 mois 1 jour

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals plans FDA meeting to discuss crofelemer clinical program for MVID, with proof-of-concept results reducing TPN. Abstract accepted for NASPGHAN 2025 Annual Meeting in Chicago

Napo Pharmaceuticals Crofelemer MVID FDA Meeting NASPGHAN 2025 Annual Meeting
BRÈVE

publiée le 14/08/2025 à 14:05, il y a 9 mois 6 jours

Croissance financière et projets futurs de Jaguar Health au deuxième trimestre 2025

Stratégie Financière Jaguar Health Croissance De Mytesi Chiffre D'affaires Du Deuxième Trimestre 2025 Recherche Sur Crofelemer
BRÈVE

publiée le 14/08/2025 à 14:05, il y a 9 mois 6 jours

Jaguar Health's Q2 2025 Financial Growth and Future Plans

Jaguar Health Financial Strategy Q2 2025 Revenue Mytesi Growth Crofelemer Research
COMMUNIQUÉ DE PRESSE

publié le 14/08/2025 à 14:00, il y a 9 mois 6 jours

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue
Jaguar Health, Inc. reports 35% revenue increase in Q2 2025 for prescription & non-prescription products, including license revenue. Mytesi prescription volume up 6.5%. Crofelemer trial yields positive results

Jaguar Health Inc. FDA Meeting Crofelemer Trial Q2 2025 Revenue Mytesi Prescription Volume

Publié le 21/05/2026 à 07:30, il y a 3 heures 14 minutes

Biophytis participe au premier Sommet de la Longévité
Publié le 21/05/2026 à 07:30, il y a 3 heures 14 minutes

Biophytis participates in the first Longevity Summit
Publié le 20/05/2026 à 18:00, il y a 16 heures 44 minutes

General shareholders meeting of 20 May, 2026
Publié le 20/05/2026 à 18:00, il y a 16 heures 44 minutes

General shareholders meeting of 20 May, 2026
Publié le 20/05/2026 à 18:00, il y a 16 heures 44 minutes

Algemene vergadering van 20 mei 2026

Voir tout LES ECHOS COMFI WIRE

Publié le 21/05/2026 à 01:25, il y a 9 heures 19 minutes

Mongolia Growth Group Announces Completion of Arrangement and Changes to the Board and Executive Leadership
Publié le 20/05/2026 à 22:40, il y a 12 heures 4 minutes

Jaguar Health Reports First Quarter 2026 Financials
Publié le 20/05/2026 à 22:15, il y a 12 heures 29 minutes

Fox River Resources Corporation Obtains Interim Order for Plan of Arrangement and Provides Details of Special Meeting
Publié le 20/05/2026 à 15:28, il y a 19 heures 16 minutes

Sarama Resources Announces Private Equity Placement of A$1.5m
Publié le 20/05/2026 à 15:01, il y a 19 heures 43 minutes

Kidoz Inc. Appoints Tarrnie Williams Jr. as Chief Operating Officer

Voir tout ACCESSWIRE

Publié le 21/05/2026 à 10:19, il y a 25 minutes

audius reports significant growth across all key metrics in the first quarter of 2026
Publié le 21/05/2026 à 10:15, il y a 28 minutes

METLEN ENERGY & METALS PLC ("Metlen" or the "Company") AGM Statement
Publié le 21/05/2026 à 10:00, il y a 44 minutes

Partners Group launches new Total Return Strategy
Publié le 21/05/2026 à 10:00, il y a 44 minutes

PUMA names Dennis Schroeder as Managing Director Europe
Publié le 21/05/2026 à 10:00, il y a 44 minutes

Nabaltec AG publishes figures for the first quarter 2026 and expects a gradual return to revenue growth starting from the second quarter

Voir tout EQS

News